Contact:
4008465777
Tonghua Dongbao partners WuXi AppTec to develop novel drugs
Date：2021-03-05
Author：東寶
Views：167
On March 5, 2021, Tonghua Dongbao and WuXi AppTec signed a strategic cooperation memorandum and a contract for the development of three Class 1 new diabetes drugs in Shanghai. Mr. Leng Chunsheng, Chairman and General Manager of Tonghua Dongbao, Mr. Li Jiahong, Chairman and General Manager of Dongbao Enterprise Group, Mr. Hu Zhengguo, Vice Chairman and Global Chief Investment Officer of WuXi AppTec, and Mr. Chen Shuhui, Executive Vice President and Chief Scientific Officer of Wuxi AppTec, were present at the signing ceremony.
The two parties will start extensive cooperation on the development of novel drugs for diabetes and other diseases by means of co-development, drug R&D services, and international cooperation. The three novel drugs include one small-molecule drug with multiple mechanisms of action and two drugs that have different mechanisms of action and routes of administration for the treatment of diabetes.
This strategic partnership is a big step forward for the Company in novel drug development, which further expands its pharmaceutical R&D portfolio for the treatment of diabetes. The drug with multiple mechanisms of action is expected to be a highly differentiated, first-in-class small-molecule drug for type 2 diabetes.
Multi-target therapeutics and new drug discovery is an important trend in the field of diabetes treatment. Hitting different targets, the three new drugs demonstrate clinical benefits beyond glucose lowering, such as weight loss and cardiovascular, renal, and hepatic protection, under different mechanisms of action, providing patients with diverse, world-class clinical solutions. Moreover, these drugs are cost-effective and provide different routes of administration, ensuring high patient compliance while securing the quality, efficacy, and safety. Hence, they are of great commercial value. They are expected to provide world-class treatments for Chinese patients.
Tonghua Dongbao and WuXi AppTec will connect on a deeper and broader level with each other in R&D, technology, and project cooperation, to explore more cooperation opportunities on top of this strategic partnership. Tonghua Dongbao will continue to keep a finger on the pulse of the cutting-edge and key therapies for diabetes and other diseases, in a bid to build a world-class R&D and commercialization platform.
